Key result
Ticagrelor did not significantly differ from clopidogrel in its effects on inflammatory biomarkers (CRP, IL-6, MPO, and sCD40L) at 4 weeks in patients with NSTE-ACS.
Why the study?
Does ticagrelor reduce inflammatory biomarkers more than clopidogrel in patients with NSTE-ACS?
RCT (n=990)
double-blind, double-dummy
randomized
Yes
Does ticagrelor reduce inflammatory biomarkers more than clopidogrel in patients with NSTE-ACS?
In patients with NSTE-ACS, ticagrelor does not provide additional anti-inflammatory benefits over clopidogrel as measured by CRP, IL-6, MPO, and sCD40L at 4 weeks.
Answers are grounded in this paper and cite their sources.
Ticagrelor offers no anti-inflammatory advantage over clopidogrel in NSTE-ACS; challenges assumptions of superior pleiotropic effects and supports selection by other factors.
BACKGROUND: Inflammation is a key factor in the development of atherosclerotic disease and acute coronary syndromes (ACS). The P2Y(12) receptor antagonists ticagrelor (AZD6140) and clopidogrel may have anti-inflammatory effects. The objective of this analysis from the Dose Confirmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2 (DISPERSE 2) trial was to compare ticagrelor and clopidogrel for effects on the inflammatory biomarkers C-reactive protein (CRP), interleukin 6 (IL-6), myeloperoxidase (MPO), and soluble CD40 ligand (sCD40L). HYPOTHESIS: Ticagrelor inhibits the P2Y(12) receptor and inflammation to a greater extent than clopidogrel in nonST-segment elevation ACS (NSTE-ACS) patients. METHODS: In a double-blind, double-dummy, multicenter trial, 990 patients who had been hospitalized within the previous 48 hours with NSTE-ACS were randomized to receive ticagrelor 90 mg twice daily, ticagrelor 180 mg twice daily, or clopidogrel 300 mg initially and then 75 mg once daily. Within the ticagrelor groups, patients were also randomized to receive or not receive a loading dose of ticagrelor 270 mg initially. All patients received standard treatment for ACS, which included 325 mg aspirin initially and 75 to 100 mg aspirin each day subsequently. Inflammatory biomarkers were measured at baseline, upon hospital discharge, and after 4 weeks. RESULTS: Inflammatory biomarker measurements were not significantly different among treatment groups at baseline, discharge, and 4 weeks. CONCLUSIONS: Ticagrelor and clopidogrel appeared not to differ in this study with respect to the inflammatory biomarkers CRP, IL-6, MPO, and sCD40L in patients with NSTE-ACS.
No takes yet. Share an insight, caveat, or question.
Husted et al. (2010) conducted an RCT in nonST-segment elevation ACS (NSTE-ACS) (n=990). Ticagrelor vs. Clopidogrel 300 mg initially then 75 mg once daily was evaluated on Inflammatory biomarkers (CRP, IL-6, MPO, and sCD40L). Ticagrelor did not significantly differ from clopidogrel in its effects on inflammatory biomarkers (CRP, IL-6, MPO, and sCD40L) at 4 weeks in patients with NSTE-ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: